Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease.
Fiche publication
Date publication
mars 2021
Journal
Advances in therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Peyrin-Biroulet L, Louis E, Loftus EV, Lacerda A, Zhou Q, Sanchez Gonzalez Y, Ghosh S
Lien Pubmed
Résumé
In the phase 2 CELEST study, positive efficacy results were obtained with the Janus kinase 1 inhibitor upadacitinib for adult patients with moderate to severe Crohn's disease. We present the health-related quality of life and work productivity improvement results with upadacitinib from CELEST.
Mots clés
CELEST, European Quality of Life-5 Dimensions Visual Analog Scale, Inflammatory Bowel Disease Questionnaire, Janus kinase 1, Quality of life, Upadacitinib, Work Productivity and Activity Impairment Questionnaire
Référence
Adv Ther. 2021 Mar 23;: